Access the full text.
Sign up today, get DeepDyve free for 14 days.
Bryony Simmons, J. Saleem, K. Heath, G. Cooke, A. Hill (2015)
Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological ResponseClinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 61
N. Martin, P. Vickerman, G. Dore, J. Grebely, A. Miners, J. Cairns, G. Foster, S. Hutchinson, D. Goldberg, T. Martin, M. Ramsay, M. Hickman (2016)
Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluationJournal of Hepatology, 65
M. Mandorfer, K. Kozbial, P. Schwabl, C. Freissmuth, R. Schwarzer, R. Stern, D. Chromy, A. Stättermayer, T. Reiberger, S. Beinhardt, W. Sieghart, M. Trauner, H. Hofer, A. Ferlitsch, P. Ferenci, M. Peck‐Radosavljevic (2016)
Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension.Journal of hepatology, 65 4
G. Ioannou, L. Beste, Michael Chang, P. Green, Elliott Lowy, J. Tsui, Feng Su, K. Berry (2016)
Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System.Gastroenterology, 151 3
M. Sulkowski, J. Eron, D. Wyles, R. Trinh, J. Lalezari, Chia Wang, J. Slim, L. Bhatti, J. Gathe, P. Ruane, R. Elion, Fritz Bredeek, Robert Brennan, G. Blick, Amit Khatri, Krystal Gibbons, Yiran Hu, L. Fredrick, G. Schnell, T. Pilot-matias, R. Tripathi, Barbara Silva-Tillmann, B. McGovern, A. Campbell, T. Podsadecki (2015)
Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.JAMA, 313 12
(2013)
Combination therapy with telaprevir for chronichepatitisCvirusgenotype1 infection in patients with HIV: a randomized trial
Anrs Cohort (2015)
Regression of liver stiffness after sustained hepatitis C virus (HCV) virological responses among HIV/HCV-coinfected patientsAIDS, 29
T. Reiberger, M. Obermeier, B. Payer, A. Baumgarten, L. Weitner, A. Moll, S. Christensen, S. Köppe, M. Kundi, A. Rieger, M. Peck‐Radosavljevic (2011)
Considerable Under-Treatment of Chronic HCV Infection in HIV Patients despite Acceptable Sustained Virological Response Rates in a Real-Life SettingAntiviral Therapy, 16
S. Lakshmi, M. Alcaide, Ana Palacio, Mohammed Shaikhomer, Abigail Alexander, Genevieve Gill-Wiehl, Aman Pandey, K. Patel, D. Jayaweera, Maria Hernandez (2016)
Improving HCV cure rates in HIV-coinfected patients - a real-world perspective.The American journal of managed care, 22 6 Spec No.
C. Oramasionwu, Heather Moore, J. Toliver (2014)
Barriers to hepatitis C antiviral therapy in HIV/HCV co-infected patients in the United States: a review.AIDS patient care and STDs, 28 5
S. Saeed, E. Strumpf, Sharon Walmsley, Kathleen Rollet-Kurhajec, N. Pick, V. Martel-Laferrière, M. Hull, M. Gill, Joseph Cox, Curtis Cooper, M. Klein, Jeff Cohen, Brian Conway, Curtis Cooper, P. Cote, Joseph Cox, John Gill, Shariq Haider, Marianne Harris, David Haase, M. Hull, Julio Montaner, Erica Moodie, N. Pick, Anita Rachlis, Danielle Rouleau, R. Sandre, Joseph Tyndall, M. Vachon, Sharon Walmsley, David Wong (2016)
How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World?Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 62
G. Dusheiko, X. Forns, F. Negro, M. Puoti, C. Sarrazin (2015)
Recommendations on Treatment of Hepatitis C 2018 q European Association for the Study of the Liver ⇑
L. Backus, P. Belperio, T. Shahoumian, T. Loomis, L. Mole (2016)
Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practiceAlimentary Pharmacology & Therapeutics, 44
L. Castéra, J. Vergniol, J. Foucher, B. Bail, E. Chanteloup, M. Haaser, M. Darriet, P. Couzigou, V. Lédinghen (2005)
Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.Gastroenterology, 128 2
B. Maasoumy, J. Vermehren, M. Welker, B. Bremer, D. Perner, C. Siederdissen, K. Deterding, P. Lehmann, G. Cloherty, B. Reinhardt, J. Pawlotsky, M. Manns, S. Zeuzem, M. Cornberg, H. Wedemeyer, C. Sarrazin (2016)
Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens.Journal of hepatology, 65 3
M. Sulkowski (2016)
HCV‐HIV co‐infected patients: no longer a ‘special’ population?Liver International, 36
M. Mandorfer, B. Payer, A. Niederecker, G. Lang, M. Aichelburg, R. Strassl, C. Boesecke, A. Rieger, M. Trauner, M. Peck‐Radosavljevic, T. Reiberger (2014)
Therapeutic potential of and treatment with boceprevir/telaprevir-based triple-therapy in HIV/chronic hepatitis C co-infected patients in a real-world setting.AIDS patient care and STDs, 28 5
M. Sulkowski, S. Pol, J. Mallolas, H. Fainboim, C. Cooper, J. Slim, A. Rivero, Carmen Mak, S. Thompson, A. Howe, L. Wenning, P. Sklar, J. Wahl, W. Greaves (2013)
Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.The Lancet. Infectious diseases, 13 7
P. Ferenci (2012)
Response guided therapy in patients with chronic hepatitis C - yesterday, today and tomorrow.Best practice & research. Clinical gastroenterology, 26 4
(2011)
Country Progress Report Austria 2011
J. Pawlotsky, A. Aghemo, G. Dusheiko, X. Forns, M. Puoti, C. Sarrazin (2018)
EASL Recommendations on Treatment of Hepatitis C 2018.Journal of hepatology, 69 2
Amit Khatri, S. Dutta, M. Dunbar, T. Podsadecki, R. Trinh, W. Awni, R. Menon (2016)
Evaluation of Drug-Drug Interactions between Direct-Acting Anti-Hepatitis C Virus Combination Regimens and the HIV-1 Antiretroviral Agents Raltegravir, Tenofovir, Emtricitabine, Efavirenz, and RilpivirineAntimicrobial Agents and Chemotherapy, 60
S. Naggie, C. Cooper, M. Saag, K. Workowski, P. Ruane, W. Towner, K. Marks, A. Luetkemeyer, R. Baden, P. Sax, E. Gane, J. Santana-Bagur, L. Stamm, Jenny Yang, P. German, H. Dvory‐Sobol, Liyun Ni, P. Pang, J. McHutchison, C. Stedman, J. Morales-Ramirez, N. Bräu, D. Jayaweera, A. Colson, P. Tebas, D. Wong, D. Dieterich, M. Sulkowski (2015)
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.The New England journal of medicine, 373 8
P. Schwabl, S. Bota, P. Salzl, M. Mandorfer, B. Payer, A. Ferlitsch, J. Stift, F. Wrba, M. Trauner, M. Peck‐Radosavljevic, T. Reiberger (2015)
New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertensionLiver International, 35
E. Gane, R. Hyland, D. An, E. Svarovskaia, P. Pang, D. Brainard, C. Stedman (2015)
Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.Gastroenterology, 149 6
T. Reiberger, A. Ferlitsch, B. Payer, M. Pinter, P. Schwabl, J. Stift, M. Trauner, M. Peck‐Radosavljevic (2012)
Noninvasive screening for liver fibrosis and portal hypertension by transient elastography—a large single center experienceWiener klinische Wochenschrift, 124
M. Mandorfer, B. Payer, B. Scheiner, F. Breitenecker, M. Aichelburg, K. Grabmeier-Pfistershammer, A. Rieger, M. Trauner, M. Peck‐Radosavljevic, T. Reiberger (2014)
Health‐related quality of life and severity of fatigue in HIV/HCV co‐infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirinLiver International, 34
M. Mandorfer, P. Schwabl, S. Steiner, B. Scheiner, D. Chromy, T. Bucsics, A. Stättermayer, M. Aichelburg, K. Grabmeier-Pfistershammer, M. Trauner, T. Reiberger, M. Peck‐Radosavljevic (2016)
Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver diseaseAIDS, 30
L. Peters, A. Mocroft, J. Lundgren, D. Grint, O. Kirk, J. Rockstroh (2014)
HIV and hepatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspectiveBMC Infectious Diseases, 14
P. Bruggmann, T. Berg, A. Øvrehus, Christophe Moreno, C. Mello, F. Roudot-thoraval, R. Marinho, M. Sherman, S. Ryder, J. Sperl, U. Akarca, İ. Balık, F. Bihl, M. Bilodeau, A. Blasco, M. Buti, F. Calinas, J. Calleja, H. Cheinquer, P. Christensen, M. Clausen, H. Coelho, M. Cornberg, M. Cramp, G. Dore, W. Doss, Ann-Sofi Duberg, M. El-Sayed, G. Ergör, G. Esmat, C. Estes, K. Falconer, J. Félix, M. Ferraz, P. Ferreira, S. Fraňková, J. García-Samaniego, J. Gerstoft, J. Gíria, F. Gonçales, E. Gower, M. Gschwantler, M. Pessoa, C. Hézode, H. Hofer, P. Husa, R. Idilman, M. Kåberg, K. Kaita, A. Kautz, S. Kaymakoğlu, M. Krajden, H. Krarup, W. Laleman, D. Lavanchy, P. Lázaro, P. Marotta, S. Mauss, M. Correa, B. Müllhaupt, Robert Myers, Francesco Negro, V. Němeček, N. Örmeci, J. Parkes, K. Peltekian, K. Peltekian, A. Ramji, H. Razavi, N. Reis, S. Roberts, W. Rosenberg, R. Sarmento-Castro, C. Sarrazin, D. Semela, G. Shiha, W. Sievert, P. Stärkel, R. Stauber, A. Thompson, P. Urbánek, I. Thiel, H. Vlierberghe, D. Vandijck, D. Vandijck, D. Vandijck, W. Vogel, I. Waked, H. Wedemeyer, N. Weis, J. Wiegand, A. Yosry, A. Zekry, P. Damme, S. Aleman, S. Aleman, S. Hindman (2014)
Historical epidemiology of hepatitis C virus (HCV) in selected countriesJournal of Viral Hepatitis, 21
M. Mandorfer, P. Schwabl, S. Steiner, T. Reiberger, M. Peck‐Radosavljevic (2016)
Advances in the management of HIV/HCV coinfectionHepatology International, 10
Sarah Burgess, N. Partovi, E. Yoshida, S. Erb, Vladimir Azalgara, T. Hussaini (2015)
Drug Interactions With Direct-Acting Antivirals for Hepatitis CAnnals of Pharmacotherapy, 49
Y. Benhamou, M. Bochet, V. Martino, F. Charlotte, F. Azria, A. Coutellier, M. Vidaud, F. Bricaire, P. Opolon, C. Katlama, T. Poynard (1999)
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patientsHepatology, 30
P. Ferenci, K. Kozbial, M. Mandorfer, H. Hofer (2015)
HCV targeting of patients with cirrhosis.Journal of hepatology, 63 4
T. Reiberger, A. Ferlitsch, W. Sieghart, A. Kreil, F. Breitenecker, A. Rieger, B. Schmied, A. Gangl, M. Peck‐Radosavljevic (2009)
HIV–HCV co‐infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertensionJournal of Viral Hepatitis, 17
B. Pernas, Marta Grandal, S. Pértega, A. Cañizares, Á. Castro‐Iglesias, A. Mena, I. Rodríguez-Osorio, A. Tabernilla, J. Pedreira, E. Poveda (2016)
Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART?The Journal of antimicrobial chemotherapy, 71 4
Amit Khatri, S. Dutta, Haoyu Wang, T. Podsadecki, R. Trinh, W. Awni, R. Menon (2016)
Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 62 8
Colette Smith, L. Ryom, R. Weber, P. Morlat, C. Pradier, P. Reiss, J. Kowalska, S. Wit, M. Law, W. Sadr, O. Kirk, N. Friis‐Møller, A. Monforte, A. Phillips, C. Sabin, J. Lundgren (2014)
Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaborationThe Lancet, 384
L. Backus, P. Belperio, T. Shahoumian, T. Loomis, L. Mole (2016)
Real‐world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment‐naive, genotype 1 hepatitis C‐infected patientsHepatology, 64
Z. Younossi, Haesuk Park, S. Gordon, J. Ferguson, Aijaz Ahmed, D. Dieterich, S. Saab (2016)
Real-world outcomes of ledipasvir/sofosbuvir in treatment-naive patients with hepatitis C.The American journal of managed care, 22 6 Spec No.
P. Schwabl, M. Mandorfer, S. Steiner, B. Scheiner, D. Chromy, M. Herac, T. Bucsics, H. Hayden, K. Grabmeier-Pfistershammer, A. Ferlitsch, Georg Oberhuber, M. Trauner, M. Peck‐Radosavljevic, T. Reiberger (2017)
Interferon‐free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver diseaseAlimentary Pharmacology & Therapeutics, 45
D. Grint, L. Peters, C. Schwarze‐Zander, M. Beniowski, C. Pradier, M. Battegay, D. Jevtović, V. Soriano, J. Lundgren, J. Rockstroh, O. Kirk, A. Mocroft, EuroSIDA EuroCOORD (2013)
Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA*HIV Medicine, 14
B. Scheiner, P. Schwabl, S. Steiner, T. Bucsics, D. Chromy, M. Aichelburg, K. Grabmeier-Pfistershammer, M. Trauner, M. Peck‐Radosavljevic, T. Reiberger, M. Mandorfer (2016)
Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver diseaseMedicine, 95
C. Graham, L. Baden, E. Yu, J. Mrus, J. Carnie, Timothy Heeren, M. Koziel (2001)
Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 33 4
(2015)
EASL Recommendations on Treatment of Hepatitis CJ. Hepatol., 63
C. Hézode, T. Asselah, K. Reddy, T. Hassanein, M. Berenguer, Katarzyna Fleischer-Stępniewska, P. Marcellin, Coleen Hall, G. Schnell, T. Pilot-matias, N. Mobashery, R. Redman, Regis Vilchez, S. Pol (2015)
Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trialThe Lancet, 385
(2016)
AlcaideM, PalacioAM, ShaikhomerM,AlexanderAL,Gill-WiehlG,etal. ImprovingHCVcurerates inHIVcoinfectedpatients –a real-worldperspective
J. Macías, Á. Camacho, M. Wichmann, L. López-Cortés, E. Ortega, C. Tural, M. Ríos, D. Merino, F. Téllez, M. Márquez, M. Mancebo, J. Pineda (2013)
Liver stiffness measurement versus liver biopsy to predict survival and decompensations of cirrhosis among HIV/hepatitis C virus-coinfected patientsAIDS, 27
C. Hawkins, Jennifer Grant, Lauren Ammerman, F. Palella, M. McLaughlin, Richard Green, Donna Mcgregor, V. Stosor (2016)
High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective.The Journal of antimicrobial chemotherapy, 71 9
T. Reiberger, B. Payer, A. Ferlitsch, W. Sieghart, F. Breitenecker, M. Aichelburg, B. Schmied, A. Rieger, M. Trauner, M. Peck‐Radosavljevic (2012)
A Prospective Evaluation of Pulmonary, Systemic and Hepatic Haemodynamics in HIV–HCV-Coinfected Patients before and after Antiviral Therapy with Pegylated Interferon and RibavirinAntiviral Therapy, 17
original article Wien Klin Wochenschr (2017) 129:517–526 DOI 10.1007/s00508-016-1162-y Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna Sebastian Steiner · Theresa Bucsics · Philipp Schwabl · Mattias Mandorfer · Bernhard Scheiner · Maximilian Christopher Aichelburg · Katharina Grabmeier-Pfistershammer · Peter Ferenci · Michael Trauner · Markus Peck-Radosavljevic · Thomas Reiberger Received: 18 August 2016 / Accepted: 19 December 2016 / Published online: 27 January 2017 © The Author(s) 2017. This article is available at SpringerLink with Open Access. Summary of SOF/LDV and 60% of 2D/3D patients prior to Aim We aimed to investigate the efficacy of interferon anti-HCV treatment due to expected DDIs. We ob- and ribavirin-free sofosbuvir/ledipasvir (SOF/LDV) served sustained virologic response (SVR) rates of and ritonavir boosted paritaprevir/ombitasvir with 100% in patients treated with SOF/LDV (19/19) and or without dasabuvir (2D/3D) regimens in a real-life 2D/3D (14/14). One 2D/3D patient was lost to follow- cohort of human immunodeficiency virus/hepatitis up, while two SOF/LDV patients died during ther- C virus (HIV/HCV) coinfected patients. The study apy from non-treatment-related causes. They were focused on efficacy, need for changes in antiretroviral excluded from the analysis. Between baseline and fol- therapy (ART) due to
Wiener klinische Wochenschrift – Springer Journals
Published: Jan 27, 2017
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.